SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Umedica Laboratories USA Inc. has received final FDA approval for sacubitril and valsartan under ANDA219946, allowing the company to enter the market for this blockbuster hypertens…
Macleods Pharmaceuticals has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA219926) for oral nintedanib esylate, facilitating market entry for th…
DR REDDYS LABS SA announced Friday the FDA approval of its undisclosed commercial drug application, with the pivotal regulatory milestone set to significantly impact the company’s …
Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study
DR REDDYS has received FDA approval for the new drug application ANDA220413, a timing that highlights the firm’s consistent manufacturing success despite current market volatility.…
The FDA has approved Monday's Brief filing for INNOGENIX INC, now awaiting data to confirm market status for the generic. This regulatory milestone positions the company for potent…
HIKMA Pharmaceuticals announced on Tuesday that the U.S. FDA approved its Abbreviated New Drug Application (ANDA 218728), signaling a positive pipeline development that positions t…
Somerset Therapeutics has received FDA approval for the intravenous formulation of sugammadex, the antidote to rocuronium bromide, marking a pivotal expansion of its portfolio. Thi…
Hikma Pharmaceuticals USA Inc. announced on Friday the approval of sugammaDEX sodium for the intravenous treatment of hyperkalemia, securing a key FDA ANDA to expand its critical c…
TEVA PHARMS USA INC announced the FDA approval of its ANDA application 214126, clearing the way for the launch of the generic version of the Blockbuster drug. This regulatory miles…
Baxter Healthcare Corporation received marketing authorization for a generic Intramuscular Diazepam solution on July 28, 2026, introducing additional pricing pressure in the Emerge…
Alembic Pharmaceuticals Inc. received FDA approval for its 6 mg prucalopride succinate tablets (ANDA 219234) on July 27, 2026, reportedly entering the market following a patent exp…
**LUPIN** announced today that it received final approval from the U.S. FDA for a new anda, entering the market for a generic with a specific launch date in July 2026. This authori…
Meitheal Pharmaceuticals Inc. announced Tuesday that the FDA has granted approval for the first generic version of GARZULYS (insulin aspart), a fast-acting subcutaneous product pre…
Hisun Pharmaceuticals USA, Inc. announced on July 23, 2026, the approval of its Abbreviated New Drug Application for intravenous fludarabine phosphate, aiming to expand accessibili…
Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System
BIOCON PHARMA received FDA approval for the ANDA-pending drug on July 22, 2026, which is expected to expand its generic market share and bolster revenue growth. This clearance allo…
Zydus Pharmaceuticals announces approval for ANDA 218349, reflecting the company's continued strategy of leveraging generic drug pipeline expansion to diversify its market revenue …
Nuvalent, Inc. received FDA approval for the oral kinase inhibitor JIDEYTRO (zidesamtinib), clearing the path for its commercial launch later this year and marking a significant ex…
MSN has announced an FDA approval for the drug identified as ANDA209526, a move likely to broaden its product portfolio in the respective therapeutic segment. The approval is expec…